Treatment of Lymphocutaneous Sporotrichosis When Other Antifungal Agents Cannot Be Tolerated
This protocol covers first-line antifungal management of lymphocutaneous sporotrichosis in patients for whom the primary treatment options are not suitable due to tolerability constraints.
Clinical Situation
The patient has lymphocutaneous sporotrichosis and requires an alternative to the agents typically used first, because they cannot tolerate those agents. This protocol defines the recommended approach for that specific scenario.
🔒
An oral antifungal agent is indicated for this situation. The full regimen — including the specific agent, dose, and clinical guidance — is available in the complete structured protocol below.
References
DOI: 10.1086/522765
- Fluconazole at a dosage of 400–800 mg daily should be used only if the patient cannot tolerate other agents (B-II).
View source ↗